Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data

References

• Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(1):30. doi:10.1186/1750-1172-5-30
   PubMedGoogle Scholar
• Arends M, Wanner C, Hughes D, et al. Characterization of Classical and Nonclassical Fabry Disease: a Multicenter Study. J Am Soc Nephrol. 2017;28(5):1631–1641. doi:10.1681/ASN.2016090964
   PubMed Web of Science ®Google Scholar
• Umer M, Kalra DK. Treatment of Fabry Disease: established and Emerging Therapies. Pharmaceuticals. 2023;16(2):320. doi:10.3390/ph16020320
   Web of Science ®Google Scholar
• Schiffman R, Hughes D, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a Kidney Disease: improving Global Outcomes(KDIGO). Controversies Conferences Kidney Int. 2017;91(2):284–293. doi:10.1016/j.kint.2016.10.004
   Google Scholar
• Beck M, Ramaswami U, Hernberg-Stahl E, et al. Twenty years of the Fabry Outcome Survey(FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Diseases. 2022;17:238. doi:10.1186/s13023-022-02392-9
   PubMed Web of Science ®Google Scholar
• Giugliani R, Hughes D, Nicholls K Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than 19 years: the Fabry outcome survey. 2023 Annual World Symposium Orlando February 22-26. 2023.
   Google Scholar
• Elliott PM, Germain DP, Hilz MJ, Spada M, Wanner C, Falissard B. Why systematic literature reviews in Fabry disease should include all published evidence. Eur J Med Genet. 2019;62(10):103702. doi:10.1016/j.ejmg.2019.103702
   PubMed Web of Science ®Google Scholar
• Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. doi:10.1186/s13023-015-0253-6
   PubMed Web of Science ®Google Scholar
• Hughes DA, Aguiar P, Deegan PB, et al. Early indicators of disease progression in FD that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open. 2020;10(10):e035182. doi:10.1136/bmjopen-2019-035182
   PubMed Web of Science ®Google Scholar
• Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1–2):49–61. doi:10.1016/j.ymgme.2022.07.010
   PubMed Web of Science ®Google Scholar
• Germain DP, Fouilhoux A, Decramer S, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96(2):107–117. doi:10.1111/cge.13546
   PubMed Web of Science ®Google Scholar
• Hughes DA, Aguiar P, Lidove O, et al. Do clinical guidelines facilitate or impede drivers of treatment in FD? Orphanet J Rare Dis. 2022;17(1):42. doi:10.1186/s13023-022-02181-4
   PubMed Web of Science ®Google Scholar
• Parini R, Pintos-Morell G, Hennermann GB, et al. Analysis of renal and cardiac outcomes in male participants in the Fabry outcome survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age. Drug Des Devel Therapy. 2020;14:2149–2158.
   PubMed Web of Science ®Google Scholar
• Hughes D, Linhart A, Gurevich A, et al. Prompt Agalsidase alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis. Drug Des Devel Ther. 2021;15:3561–3572. doi:10.2147/DDDT.S313789
   PubMed Web of Science ®Google Scholar
• van der Veen S, El Sayed M, Hollak C, et al. Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels Clin. J Am Soc Nephrol. 2023. doi:10.2215/CJN.0000000000000239
   Web of Science ®Google Scholar
• Jaurretche S, Conde H, Gonzalez Schain A, et al. Biomarkers for Monitoring Renal Damage Due to FD in Patients Treated with Migalastat: a Review for Nephrologists. Genes. 2022;13(10):1751. doi:10.3390/genes1310175
   PubMed Web of Science ®Google Scholar
• Beck M, Ricci R, Widmer U, et al. FD: overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004;34:838. doi:10.1111/j.1365-2362.2004.01424.x
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alfa-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9.
   PubMed Web of Science ®Google Scholar
• Bénichou B, Goyal S, Sung C, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase alfa beta on efficacy during enzyme replacement therapy for FD. Mol Genet Metab. 2009;96:4.
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Hollak CE, Donker-Koopman WE, et al. Enzyme therapy for FD: neutralizing antibodies toward agalsidase alfa and beta. Kidney Int. 2004;66:1589–1595.
   PubMed Web of Science ®Google Scholar
• Lenders M, Brand E. Front Immunol Assessment and impact of dose escalation on anti-drug antibodies in FD. Int J Med. 2022;13:1024963. doi:10.3389/fimmu.2022.1024963
   Google Scholar
• Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in FD: a randomized controlled trial. JAMA. 2001;285(21):2743–2749. doi:10.1001/jama.2
   PubMed Web of Science ®Google Scholar
• Lenders M, Neußer LP, Rudnicki M, et al. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Anti-drug Antibody Titers and Clinical Outcome in Patients with Fabry Disease. J Am Soc Nephrol. 2018;29(12):2879–2889. doi:10.1681/ASN.2018070740
   PubMed Web of Science ®Google Scholar
• Lenders M, Oder D, Nowak A, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282(3):241–253.
   PubMed Web of Science ®Google Scholar
• Baig S, Edward NC, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018;20(FI2):f153–f161. doi:10.1093/europace/eux261
   PubMedGoogle Scholar
• Frustaci A, Verardo R, Grande C, et al. Immune-Mediated Myocarditis in Fabry Disease Cardiomyopathy. J Am Heart Assoc. 2018;7(17):e009052. doi:10.1161/JAHA.118.009052
   PubMed Web of Science ®Google Scholar
• Chimenti C, Scopelliti F, Vulpis E, et al. Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. Hum Pathol. 2015;46(11):1760–1768. doi:10.1016/j.humpath.2015.07.017
   PubMed Web of Science ®Google Scholar
• Chimenti C, Hamdani N, Boontje NM, et al. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol. 2008;172(6):1482–1490. doi:10.2353/ajpath.2008.070576
   PubMed Web of Science ®Google Scholar
• Pieroni M, Moon JC, Arbustini E, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922–936. doi:10.1016/j.jacc.2020.12.024
   PubMed Web of Science ®Google Scholar
• Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–618. doi:10.1161/01.cir.55.4.613
   PubMed Web of Science ®Google Scholar
• Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8(3):479–482. doi:10.1080/10976640600605002
   PubMed Web of Science ®Google Scholar
• De Cobelli F, Esposito A, Perseghin G, et al. Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI. AJR Am J Roentgenol. 2012;198(4):809–816. doi:10.2214/AJR.11.7118
   PubMed Web of Science ®Google Scholar
• Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94(2):153–158. doi:10.1136/hrt.2006.104026
   PubMed Web of Science ®Google Scholar
• Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet. 2009;374(9706):1986–1996. doi:10.1016/S0140-6736(09)61493-8
   PubMed Web of Science ®Google Scholar
• Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2015;3:21–27. doi:10.1016/j.ymgmr.2015.02.002
   PubMed Web of Science ®Google Scholar
• Hughes DA, Barba Romero MÁ, Hollak CE, et al. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--The Fabry Outcome Survey. Mol Genet Metab. 2011;103(3):207–214. doi:10.1016/j.ymgme.2011.03.022
   PubMed Web of Science ®Google Scholar
• Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125. doi:10.1186/s13023-015-0338-2
   PubMed Web of Science ®Google Scholar
• Ramaswami U, Beck M, Hughes D, et al. Cardio-Renal Outcomes With Long-Term Agalsidase Alfa Enzyme Replacement Therapy: a 10-Year Fabry Outcome Survey (FOS) Analysis. Drug Des Devel Ther. 2019;13:3705–3715. doi:10.2147/DDDT.S207856
   PubMed Web of Science ®Google Scholar
• Feriozzi S, Linhart A, Ramaswami U, et al. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with FD Treated with Agalsidase Alfa: a Fabry Outcome Survey Study. Clin Ther. 2020;42(12):2321–2330.e0. doi:10.1016/j.clinthera.2020.10.007
   PubMed Web of Science ®Google Scholar
• Kampmann C, Linhart A, Baehner T, et al. Onset and progression of the Anderson–Fabry disease-related cardiomyopathy. Int J Cardiol. 2008;130:367–373. doi:10.1016/j.ijcard.2008.03.007
   PubMed Web of Science ®Google Scholar
• Ramaswami RC, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:127. doi:10.1186/s13023-015-0338-2
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: progressive cardiomyocyte enlargement leads to increased cell death and fibrosis and correlates with severity of ventricular hypertrophy. Int J Cardiol. 2017;248:257–262. doi:10.1016/j.ijcard.2017.06.079
   PubMed Web of Science ®Google Scholar
• Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119(4):524–529. doi:10.1161/CIRCULATIONAHA.108.794529
   PubMed Web of Science ®Google Scholar
• Frustaci A, Verardo R, Scialla R, et al. Downregulation of Mannose-6-Phosphate Receptors in Fabry Disease Cardiomyopathy: a Potential Target for Enzyme Therapy Enhancement. J Clin Med. 2022;11(18):5440. doi:10.3390/jcm11185440.8
   PubMed Web of Science ®Google Scholar
• Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet.2015;52(5):353–358.
   PubMed Web of Science ®Google Scholar
• Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016;375(6):545–555. doi:10.1056/NEJMoa1510198
   PubMed Web of Science ®Google Scholar
• Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076–1096. doi:10.1002/ejhf.1960
   PubMed Web of Science ®Google Scholar
• Dehout F, Schwarting A, Beck M, et al. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data. Acta Paediatr Suppl. 2003;92(443):14–15. doi:10.1111/j.1651-2227.2003.tb00214.x
   PubMedGoogle Scholar
• Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol. 2006;66(2):77–84
   PubMed Web of Science ®Google Scholar
• West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20(5):1132–1139. doi:10.1681/ASN.20080808708
   PubMed Web of Science ®Google Scholar
• Whybra C, Miebach E, Mengel F, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med. 2009;11:441–449. doi:10.1097/GIM.0b013e3181a23bec
   PubMed Web of Science ®Google Scholar
• Feriozzi S, Schwarting A, Sunder-Plassmann G. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol. 2009;29(5):353–361. doi:10.1159/000168482
   PubMed Web of Science ®Google Scholar
• Ramaswami U, Parini R, Kampmann C, Beck M. Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatr. 2011;100(4):605–611. doi:10.1111/j.1651-2227.2010.02101.x
   PubMed Web of Science ®Google Scholar
• Ramaswami U. FD in children and response to enzyme replacement therapy: results from Fabry Outcome Study. Clin Genet. 2012;81(5):485–490. doi:10.1111/j.1399-0004.2011.01671
   PubMed Web of Science ®Google Scholar
• Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol. 2012;7(1):60–69. doi:10.2215/CJN.03130411
   PubMed Web of Science ®Google Scholar
• Goker Alpan O, Longo N, McDonald M, et al. An open-label trial of agalsidase alfa enzyme replacement therapy in children with FD who are naïve to enzyme replacement therapy. Drug Des Devel Ther. 2016;10:1771–1781. doi:10.2147/DDDT.S102761
   PubMed Web of Science ®Google Scholar
• Beck M, Hughes D, Kampmann C, et al. Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events. Mol Genet Metab Rep. 2017;14:31–35. doi:10.1016/j.ymgmr.2017.10.008
   PubMed Web of Science ®Google Scholar
• Cybulla M, Nicholls K, Feriozzi S. Renoprotective Effect of Agalsidase alfa: a Long-Term Follow-Up of Patients with FD. CJ Clin Med. 2022;11(16):4810. doi:10.3390/jcm11164810
   Web of Science ®Google Scholar
• Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol. 2014;10:493–503. doi:10.1038/nrneph.2014.11432
   PubMed Web of Science ®Google Scholar
• Battaglia Y, Bulighin F, Zerbinati L, et al. Dapagliflozin on Albuminuria in Chronic Kidney Disease Patients with Fabry Disease: the DEFY Study Design and Protocol. J Clin Med. 2023;12(11):3689. doi:10.3390/jcm12113689
   PubMed Web of Science ®Google Scholar
• Lenders M, Schmitz B, Stypmann J, et al. Renal function predicts long-term outcomes for enzyme replacement therapy in patients with FD. Nephrol Dial Transplant. 2017;32:2090e2097. doi:10.1093/ndt/gfw334
   Web of Science ®Google Scholar
• Feriozzi S. Rozenfeld P Pathology and pathogenic pathways in Fabry nephropathy. Clin Exp Nephrol. 2021;25(9):925–934. doi:10.1007/s10157-021-02058-z
   PubMed Web of Science ®Google Scholar
• Jehn U, Bayraktar S, Pollmann S, et al. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes. Int J Mol Sci Int J Mol Sci. 2021;22(21):11339. doi:10.3390/ijms222111339
   PubMed Web of Science ®Google Scholar
• Hopkin RJ, Cabrera GH, Jefferies JL, et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry. Mol Genet Metab. 2023;138(2):106967. doi:10.1016/j.ymgme.2022.106967
   PubMed Web of Science ®Google Scholar
• Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet. 2023;60(7):722–731. doi:10.1136/jmg-2022-108669
   PubMed Web of Science ®Google Scholar
• Riccio E, Sabbatini M, Bruzzese D, et al. Glomerular Hyperfiltration: an Early Marker of Nephropathy in Fabry Disease. Nephron. 2019;141(1):10–17. doi:10.1159/000493469
   PubMed Web of Science ®Google Scholar
• Feriozzi S, Germain DP, Di Vito R, et al. Cystatin C as a marker of early renal function changes in Fabry nephropathy. J Nephrol. 2007;20(4):437–443
   PubMed Web of Science ®Google Scholar
• Cybulla M, Kurschat C, West M, et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol. 2013;26(4):645–651. doi:10.5301/jn.5000214
   PubMed Web of Science ®Google Scholar
• Sharma A, Sartori M, Zaragoza JJ, et al. Fabry’s disease: an example of cardiorenal syndrome type 5. Heart Fail Rev. 2015;20(6):689–708. doi:10.1007/s10741-015-9500-0
   PubMed Web of Science ®Google Scholar
• Pieroni M, Moon JC, Arbustini E, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922–936. doi:10.1016/j.jacc.2020.12.024
   PubMed Web of Science ®Google Scholar
• Weidemann F, Beer M, Kralewski M, et al. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. Mol Genet Metab. 2019;126(2):169–182. doi:10.1016/j.ymgme.2018.11.005
   PubMed Web of Science ®Google Scholar
• Üçeyler N, Ganendiran S, Kramer D, et al. Characterization of pain in Fabry disease. Clin J Pain. 2014;30:915–920. doi:10.1097/AJP.0000000000000041
   PubMed Web of Science ®Google Scholar
• Marchesoni CL, Roa N, Pardal AM, et al. Misdiagnosis in Fabry disease. J Pediatr. 2010;156:828831. doi:10.1016/j.jpeds.2010.02.012
   Web of Science ®Google Scholar
• Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007;23:535–542. doi:10.1097/AJP.0b013e318074c986
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Hauer P, Freeman B, et al. Enzyme replacement therapy and Intraepidermal innervation density in Fabry disease. Muscle Nerve. 2006;34:53–56. doi:10.1002/mus.20550
   PubMed Web of Science ®Google Scholar
• Ries M, Clarke J, Whybra C, et al. Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease. Pediatrics. 2006;118:924–932. doi:10.1542/peds.2005-2895
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr. 2010;156:832–7, 837.e1.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Deegan PB, Milligan A, et al. A randomized, double-blind, placebo--controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2013;109(3):269–275. doi:10.1016/j.ymgme.2013.04.015
   PubMed Web of Science ®Google Scholar
• Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One. 2007;2(7):e598. doi:10.1371/journal.pone.0000598
   PubMed Web of Science ®Google Scholar
• Lenders M, Canaan-Kühl S, Krämer J, et al. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch–2-Year Follow-Up. J Am Soc Nephrol. 2016;27:952–962. doi:10.1681/ASN.2015030337
   PubMed Web of Science ®Google Scholar
• Ghali J, Nicholls K, Denaro C, et al. effect of reduced agalsidase beta dosage in Fabry patients: the Australian experience. JIMD Rep. 2012;3:33–43. doi:10.1007/8904_2011_44
   PubMedGoogle Scholar
• Weidemann F, Kramer J, Duning T, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25:837–849. doi:10.1681/ASN.2013060585
   PubMed Web of Science ®Google Scholar
• Bongiorno MR, Pistone G, Arico M. Fabry disease: enzyme replacement therapy. J Eur Acad Dermatol Venereol. 2003;17:676–679. doi:10.1046/j.1468-3083.2003.00831.x
   PubMed Web of Science ®Google Scholar
• Jardim LB, Gomes I, Netto CB, et al. Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease. J Inherit Metab Dis. 2006;29:653–659. doi:10.1007/s10545-006-0339-3
   PubMed Web of Science ®Google Scholar
• Ghali J, Murugasu A, Day T, et al. Carpal tunnel syndrome in Fabry disease. JIMD Rep. 2012;2:17–23. doi:10.1007/8904_2011_37
   PubMedGoogle Scholar
• Kampmann C, Kalkum G. Beck M Successful long-term enzyme replacement therapy in a young adult with Fabry disease, Clin. Genet. 2013;83:395–396. doi:10.1111/j.1399-0004.2012.01916.x
   Web of Science ®Google Scholar
• Karras A, De Lentdecker P, Delahousse M, et al. Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era. Am J Transplant. 2008;8:1345–1348, 10.1111/j.1600–6143.2008.02245.x.
   PubMed Web of Science ®Google Scholar
• Nicholls K, Bleasel K. Becker G Severe infusion reactions to Fabry enzyme replacement therapy: rechallenge after tracheostomy. JIMD Rep. 2012;5:109–112. doi:10.1007/8904_2011_106
   PubMedGoogle Scholar
• Pieroni M, Camporeale A, Della Bona R, et al. Progression of Fabry cardiomyopathy despite enzyme replacement therapy. Circulation. 2013:128 1687–1688. doi:10.1161/CIRCULATIONAHA.113.002799
   PubMed Web of Science ®Google Scholar
• El Dib R, Gomaa H, Carvalho RP, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;7(7):CD006663. doi:10.1002/14651858.CD006663.pub4
   PubMedGoogle Scholar
• Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539–548. doi:10.1097/01.gim.0000237866.70357.c6
   PubMed Web of Science ®Google Scholar
• Politei JM, Bouhassira D, Germain DP. Practical Recommendations for Diagnosis and Treatment CNS. Neurosci Ther. 2016;22:568–576. doi:10.1111/cns.12542
   PubMed Web of Science ®Google Scholar
• Chertcoff A, León Cejas L, Marchesoni C, et al. Depression: the Hidden Problem in Fabry Disease. J Inborn Error Metabol Screen. 2021;9:e20210015. doi:10.1590/2326-4594-JIEMS-2021-0015
   Google Scholar
• Bates D, Schultheis BC, Hanes MC, et al. Comprehensive Algorithm for Management of Neuropathic Pain. Pain Med. 2019;20(Suppl 1):S2–S12. doi:10.1093/pm/pnz075.s248
   PubMedGoogle Scholar
• Mücke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3). doi:10.1002/14651858
   PubMedGoogle Scholar
• Mehta A, Ginsberg L, FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta PædiatricaSuppl. 2005;94(447):24–27. doi:10.1111/j.1651-2227.2005.tb02106.x
   Google Scholar
• Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke. 2009;40:788–794. doi:10.1161/STROKEAHA.108.526293.
   PubMed Web of Science ®Google Scholar
• Reisin RC, Mazziotti J, Cejas LL, et al. Prevalence of Fabry Disease in Young Patients with Stroke in Argentina. J Stroke Cerebrovasc Dis. 2018;27:575–582. doi:10.1016/j.jstrokecerebrovasdis.2017.09.045
   PubMed Web of Science ®Google Scholar
• Rolf A, FFazekas S, Grittner U, et al. Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013;44:340–349. doi:10.1161/STROKEAHA.112.663708.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2006;448:337–343. doi:10.1007/s00428-005-0089-x
   PubMed Web of Science ®Google Scholar
• Okeda R and Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology. 2008;28:532–540. doi:10.1111/j.1440-1789.2008.00883.x
   PubMed Web of Science ®Google Scholar
• Ortiz A, Abiose A, Bichet DG, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase b: data from the Fabry Registry. J Med Genet. 2016;53:495–502. doi:10.1136/jmedgenet-2015-103486
   PubMed Web of Science ®Google Scholar
• Sheng S, Wu L, Nalleballe K, et al. Fabry’s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci. 2019l;65:83–86. doi:10.1016/j.jocn.2019.03.064
   PubMed Web of Science ®Google Scholar
• Fellgiebel A, Gartenschläger M, Wildberger K, et al. Enzyme Replacement Therapy Stabilized White Matter Lesion Progression inFabry. Disease Cerebrovasc Dis. 2014;38:448–456. doi:10.1159/000369293
   PubMed Web of Science ®Google Scholar
• Rost NS, Cloonan L, Kanakis AS, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology. 2016;86(20):1880–1886. doi:10.1212/WNL.0000000000002673
   PubMed Web of Science ®Google Scholar
• Lenders M, Karabul N, Duning T, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology. 2015;84(10):1009–1016. doi:10.1212/WNL.0000000000001333
   PubMed Web of Science ®Google Scholar
• Ferrari G, Reisin R, Kisinovsky I, et al. Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa MEDICINA (Buenos Aires). Medicine. 2021;81:173–179.
   Google Scholar
• Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003;28:703–710. doi:10.1002/mus.20550
   PubMed Web of Science ®Google Scholar
• Hegemann S, Conti G. Agalsidase alfa and hearing in FD: data from the Fabry Outcome Survey. Eur J Clin Invest. 2006;36(9):663–667. doi:10.1111/j.1365-2362.2006.01701.x
   PubMed Web of Science ®Google Scholar
• Sergi B, Conti G, Paludetti G, et al. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. Interdisciplinary Study Group On FD. Acta Otorhinolaryngol Ital. 2010;30(2):87–93.
   PubMed Web of Science ®Google Scholar